Current and historical daily PE Ratio for Fresenius SE & Co KGaA (
) from 1992 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Fresenius SE & KGaA stock (XTER:FRE) PE ratio as of Apr 19 2024 is 0.
More Details
Fresenius SE & Co KGaA (XTER:FRE) PE Ratio (TTM) Chart
Fresenius SE & Co KGaA (XTER:FRE) PE Ratio (TTM) Historical Data
View and export this data going back to 1992. Start your Free Trial
Total 1233
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Fresenius SE & KGaA PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-12 | At Loss |
| 2024-03-15 | At Loss | 2024-01-11 | At Loss |
| 2024-03-14 | At Loss | 2024-01-10 | At Loss |
| 2024-03-13 | At Loss | 2024-01-09 | At Loss |
| 2024-03-12 | At Loss | 2024-01-08 | At Loss |
| 2024-03-11 | At Loss | 2024-01-05 | At Loss |
| 2024-03-08 | At Loss | 2024-01-04 | At Loss |
| 2024-03-07 | At Loss | 2024-01-03 | At Loss |
| 2024-03-06 | At Loss | 2024-01-02 | At Loss |
| 2024-03-05 | At Loss | 2023-12-29 | At Loss |
| 2024-03-04 | At Loss | 2023-12-28 | At Loss |
| 2024-03-01 | At Loss | 2023-12-27 | 57.9 |
| 2024-02-29 | At Loss | 2023-12-22 | 58.4 |
| 2024-02-28 | At Loss | 2023-12-21 | 58.3 |
| 2024-02-27 | At Loss | 2023-12-20 | 58.1 |
| 2024-02-26 | At Loss | 2023-12-19 | 56.7 |
| 2024-02-23 | At Loss | 2023-12-18 | 56.6 |
| 2024-02-22 | At Loss | 2023-12-15 | 57.3 |
| 2024-02-21 | At Loss | 2023-12-14 | 58.3 |
| 2024-02-20 | At Loss | 2023-12-13 | 57.7 |
| 2024-02-19 | At Loss | 2023-12-12 | 57.8 |
| 2024-02-16 | At Loss | 2023-12-11 | 57.6 |
| 2024-02-15 | At Loss | 2023-12-08 | 58.2 |
Fresenius SE & Co KGaA (XTER:FRE) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Fresenius SE & Co KGaA
ISIN : DE0005785604
Share Class Description:
XTER:FRE: Ordinary SharesCompare
Compare
Traded in other countries / regions
FRE.Germany0OO9.UKFSNUY.USAFRE.Austria1FRE.ItalyFREN.Mexico IPO Date
1992-08-06Description
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers